TABLE 1.

Research questions addressed by the working group

Does the diagnostic accuracy of molecular analysis by nucleic acid amplification and serologic tests for SARS-CoV2 differ between children with CLD or immunosuppressed for LT and the pediatric general population?

Does SARS-CoV2 infection cause acute liver injury in children with or without CLD?

Does MIS-C cause acute liver injury in children?

Is CLD a risk factor for acquiring SARS-CoV2 or for a more severe infection in children?

Does SARS-CoV2 infection cause acute liver failure in children?

Balancing the risk of a hepatic disease flare and the estimated risk of SARS-CoV2 infection, should uninfected children with CLD on treatment with immunomodulators and biologic therapies continue their medical treatment?

Balancing the risk of a hepatic disease flare and the estimated risk of SARS-CoV2 infection, should infected children with liver diseases on treatment with immunomodulators and biologic therapies continue their medical treatment?

Balancing the risk of graft rejection and the estimated risk of SARS-CoV2 infection, should uninfected LT children continue their immunosuppressive regime?

Balancing the risk of graft rejection and the estimated risk of SARS-CoV2 infection, should infected LT children continue their immunosuppressive regime?

Balancing the risk of the condition underlying indication to liver transplantation and the estimated risk of SARS-CoV2 infection, should deceased donor liver transplant be avoided in case of ongoing SARS-CoV2 donor/recipient infection?

Are the same behavioral measures used by the general population during the pandemic (e.g., hand hygiene, and social distancing) recommended for decreasing the risk of contracting SARS-CoV2 in children with CLD, immunosuppressed for autoimmune liver diseases, and recipients of LT?

CLD = chronic liver disease; LT = liver transplantation; SARS-CoV2 = severe acute respiratory syndrome coronavirus type 2.